Abstract:A growing collection of evidence exists to support a role for non-neuronal cells in Alzheimer’s Disease (AD) pathogenesis. Although less widely studied, neuroimaging and neuropathology data suggests that dysregulation of oligodendrocytes (OLs) and subsequent dysmyelination of axons appears to be a critical initiating event in stimulating AD pathology. Despite these intriguing preliminary data, the precise molecular networks and genetic targets in OLs that are involved in initiating the AD process have yet to be elucidated. We applied a series of molecular network analysis techniques to a large data set of human postmortem gene expression data from AD patient brain samples, including coexpression networks, causal Bayesian networks, key driver analysis, and network annotation tools. This integrative network approach allowed us to integrate data from a diverse set of modalities and thereby identify critical pathways and genes that are altered within OLs in AD. We find that an AD coexpression network of OL-associated genes is not only highly correlated with AD pathological traits but also enriched for the known AD GWAS risk genes. Further, we demonstrate that this network is strongly dysregulated at the expression level in brain samples from AD patients. We further dissect the molecular regulation patterns of OLs in AD to identify key drivers of the OL network including PSEN1, UGT8, CNP, MYRF, and PLP1. We show that in vitro and in vivo perturbations of the key drivers within the gene-gene interaction network mimic key aspects of gene expression dysregulation in human AD brain samples. Our data also suggests PSEN1, whose mutations have been identified in early-onset familial AD, plays a key role in the dys-regulation of myelination in the more common late-onset AD. Our network analysis of oligodendrocytes in AD further strengthens the existing evidence that OLs play a role in AD. Importantly, our results also suggest key pathways through which OLs may help mediate AD pathogenesis.

Oligodendrocytes in amyotrophic lateral sclerosis and frontotemporal dementia: the new players on stage

Disease-Associated Oligodendrocyte: New Player in Alzheimer's Disease and CNS Pathologies

New perspectives on cytoskeletal dysregulation and mitochondrial mislocalization in amyotrophic lateral sclerosis

Immune Signaling Kinases in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)

Axonopathy Underlying Amyotrophic Lateral Sclerosis: Unraveling Complex Pathways and Therapeutic Insights

Oligodendrocytes and myelin: Active players in neurodegenerative brains?

The genetics and neuropathology of amyotrophic lateral sclerosis

Recent Updates on the Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Molecular and Cellular Mechanisms Affected in ALS

Author Correction: A Shared Disease-Associated Oligodendrocyte Signature among Multiple CNS Pathologies

Links between electrophysiological and molecular pathology of amyotrophic lateral sclerosis

Recognizing Alzheimer's disease from perspective of oligodendrocytes: Phenomena or pathogenesis?

Protein aggregation and therapeutic strategies in SOD1- and TDP-43- linked ALS

F2‐01‐01: Oligodendrocyte‐Enriched Gene Networks Reveal Novel Pathways and Key Targets in the Pathogenesis of Alzheimer’s Disease

The Key Role of Astrocytes in Amyotrophic Lateral Sclerosis and Their Commitment to Glutamate Excitotoxicity

Autophagy and neurodegeneration: Unraveling the role of C9ORF72 in the regulation of autophagy and its relationship to ALS-FTD pathology

Disease-associated oligodendroglia: a putative nexus in neurodegeneration

Is Amyotrophic Lateral Sclerosis/frontotemporal Dementia an Autophagy Disease?

Inherited and Sporadic Amyotrophic Lateral Sclerosis and Fronto-Temporal Lobar Degenerations arising from Pathological Condensates of Phase Separating Proteins.

Neurofilament accumulations in amyotrophic lateral sclerosis patients' motor neurons impair axonal initial segment integrity

Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer’s Disease, Parkinson’s Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis